Adlai Nortye (ANL): Projected Price to Earnings

Graphic logo of Adlai Nortye Ltd (ANL)

The strategic goal of Adlai Nortye Ltd. (ANL) is to achieve financial autonomy through cash reserves, bypassing the influence of GDP. The expected P/E multiple valuation of the company on the GURU.Markets system's dynamic chart captures progress, where the value of 0.00 serves as the current indicator. Barriers include the necessity of developing centers in the US and China, as well as adapting software to global regulatory standards.

Future Price to Earnings Multiple: Adlai Nortye Ltd. (ANL) for 02/21/2024 - 11/17/2026

Analytical breakdowns for Adlai Nortye Ltd.

- stock quotes and analyst forecast:
Summary company analytics:ANL Adlai Nortye Limited
Brand item of Adlai Nortye Limited

The forward P/E assesses the value of Adlai Nortye Ltd. (ANL) shares relative to expected earnings, allowing investors to determine the premium paid for future business growth rates. Analyzing the current forward P/E level of Adlai Nortye Ltd. (ANL) reveals how market expectations are adjusting under pressure from competition by pharma behemoths and the risks of losing patent exclusivity for its primary oncology drug, buparlisib.

Competing companies

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings xiliotx.com (XLO)|Renovaro - Price to Future Earnings Ratio|Future Price to Earnings Mural Oncology MURA|KAPA - Projected Price to Earnings|OKUR - Future Price to Earnings|GDTC - Forward P/E Multiple|Curis, Inc. (CRIS) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple